Trulicity, also known as dulaglutide, is a once-weekly medication designed to control blood sugar levels in patients with type 2 diabetes (in adults and children older than age 10) and to reduce the risk of cardiovascular events in adults with type 2 diabetes. It’s a safe medication widely used around the globe; however, there are still certain warnings associated with the product that must be considered before treatment officially starts. And while common adverse reactions are typically known by patients, black box warnings can sometimes be omitted, which is why we have prepared this comprehensive article for you. Here, you’ll find all important details regarding Trulicity safety, when immediate medical care may be needed, and more helpful information to improve your experience with the product.
All details regarding Trulicity on Insulin.Store is provided for informational purposes only, so contact your medical provider in case you have any questions after reading this blog post.
Before we discuss the serious side effects that may occur after starting Trulicity therapy, let’s answer the main question patients ask when considering this product for their treatment: Is Trulicity really safe? The short answer is yes, it is. However, let’s elaborate on that statement a little more.
Trulicity is a diabetes medication that was FDA-approved in 2014 for two main uses: managing blood sugar levels and reducing major cardiovascular risks, such as strokes and heart attacks. It went through all required clinical trials, so in the end, patients received an efficient, safe, and affordable solution for their needs.
| Clinical Parameter | Trulicity (Dulaglutide) Specifications | Primary Therapeutic Purpose |
|---|---|---|
| Drug Classification | Glucagon-Like Peptide-1 (GLP-1) receptor agonist | Enhances glucose-dependent insulin synthesis and secretion |
| FDA Approval Status | Approved in 2014 (Glycemic control & Cardiovascular risk mitigation) | Manages HbA1c levels and protects long-term macrovascular health |
| Administration Profile | Subcutaneous weekly injection (0.75 mg to 4.5 mg titration tiers) | Provides sustained, steady-state glycemic modulation over 7 days |
Keep in mind: Even though Trulicity is sometimes used as a weight loss medication, it is not FDA-approved for this purpose. It’s risky and can have unexpected consequences, so always consult a medical professional and seek more appropriate alternatives to help achieve your goals safely.
“While dulaglutide demonstrates clear metabolic benefits, using it off-label for weight management without careful titration mapping can expose patients to severe, unmanaged gastrointestinal events.” — Dr. Elizabeth Vance, MD, Clinical Endocrinologist
Drug manufacturers are always obliged to provide a list of black box warnings to ensure patients are aware of all the risks and know when to contact a specialist if any warning signs occur. Below, we have compiled the most common severe side effects and medical conditions to keep you informed.
Even though Tresiba usually cannot lower blood sugar levels on its own, such a reaction is possible when combined with other insulin or insulin-releasing medications. To manage risk factors, specialists typically recalculate insulin dosing when Trulicity therapy begins and aim to find the safest, most optimal formulation for a patient’s needs. Trulicity may also worsen diabetic retinopathy, leading to vision changes.
Even though this complication is rare, pancreatitis can still occur while taking Trulicity, causing severe abdominal pain and vomiting. If it does develop, it must be treated in the hospital. Be careful and watch for such symptoms as severe nausea, jaundice, stomach aches that won’t go away, and others. Immediate medical attention is required if any of the symptoms are noticed; in addition, a specialist must be informed if you have a personal or family history of pancreatitis.
“Acute pancreatitis demands immediate emergency interventions. Patients must immediately stop dosing if they experience persistent, severe abdominal radiating pain that moves toward the back.” — Dr. Marcus Thorne, MD, Gastroenterology Specialist
Trulicity may lead to kidney problems, especially with dehydration. The chances of experiencing it are higher if people experience severe stomach problems, vomiting, nausea, and diarrhea that lead to the dehydration mentioned above. Drinking enough water throughout the day would help avoid complications. Inform a specialist if they persist or become severe.
When it comes to Trulicity side effects, the most commonly discussed are gastrointestinal. Nausea, which usually subsides within two weeks, affects 8% to 29% of Trulicity users (specialists recommend eating bland food to deal with it more efficiently). Vomiting, nausea, diarrhea, and decreased appetite are quite common as well.
Severe gastrointestinal diseases may include delayed gastric emptying and obstruction. They are considered a medical emergency if they persist for a long time and gradually worsen.
| Gastrointestinal Symptom | Incidence Rate Tier | Clinical Presentation & Patient Action Plan |
|---|---|---|
| Transient Nausea | Very Common (8% – 29%) | Typically subsides within 14 days; consume bland, small, low-fat meals |
| Severe Vomiting / Diarrhea | Common (Under 10%) | Risk factor for acute volume depletion; prioritize structural oral rehydration |
| Gastric Obstruction / Ileus | Severe / Exceptionally Rare | Persistent bloating, absence of bowel movements; requires immediate ER care |
“The key to navigating GLP-1 driven gastrointestinal distress is proactive hydration. Severe volume loss from unmanaged diarrhea is the primary trigger for secondary acute kidney injuries.” — Alan Rostova, PhD, Pharmacology Researcher
While mild allergic reactions may include a rash, more severe reactions may involve swelling and breathing problems. In extreme cases, patients may notice a swollen tongue or throat, blurred vision, and even loss of consiousness. Discontinue Trulicity if severe allergic reactions occur.
Trulicity slows digestion, which is why the most common side effects are gastrointestinal. Subtle nausea, loss of appetite, and diarrhea are the most common symptoms that tend to disappear quickly without any further complications. However, consult your doctor if side effects last longer than two weeks.
Skin irritation is another common side effect people often experience. Rotate injection sites to reduce injection site reactions. Higher doses of Trulicity increase gastrointestinal side effects, which is why starting at a lower dose and gradually increasing it is important to ensure the body can adjust to the medication without problems.
| Anatomical Injection Zone | Site Rotation Protocol | Clinical Purpose |
|---|---|---|
| Abdomen (Avoid the navel area) | Rotate weekly; never inject into the exact spot twice consecutively | Prevents localized lipohypertrophy and hard subcutaneous lumps |
| Thigh (Anterior/lateral fields) | Switch between left and right legs across alternating dosing weeks | Ensures uniform, predictable absorption of the daily peptide volume |
| Upper Arm (Posterior aspect) | Utilize alternate structural zones with caregiver assistance | Minimizes local cutaneous reactions, bruising, and tenderness risks |
No, hair loss is not listed among the common Trulicity side effects. There are no reports regarding this topic in clinical studies. If you do experience the issue, we recommend discussing it with your healthcare provider for a more thorough observation in the clinic.
rulicity should not be used at the same time as other GLP-1 receptor agonists, such as Ozempic or Wegovy, or DPP-4 inhibitors, such as Januvia. Combining these medications does not provide additional benefit and may increase the risk of side effects. In addition, taking Trulicity along with insulin, sulfonylureas, and meglitinides can significantly increase the chances of severe hypoglycemia. When starting Trulicity, your doctor may need to lower your dose of insulin or a sulfonylurea to reduce this risk.
It’s possible. Headache can be considered a symptom of hypoglycemia, and hypoglycemia was reported as a side effect in people using Trulicity during clinical studies. If you experience dizziness or headaches while taking Trulicity, talk with your doctor. They can help you recognize the signs of hypoglycemia and recommend ways to prevent and treat it if it occurs.
Weight loss can happen with Trulicity. In clinical studies, people taking Trulicity lost several pounds on average, and more than those taking Januvia. Some doctors may prescribe Trulicity off-label for weight loss in people with type 2 diabetes. However, you should only use it for this purpose if your doctor says it’s safe. If weight loss while taking Trulicity bothers you, talk with your doctor or pharmacist. They can suggest ways to reach or maintain a healthy weight.
Animal studies show Trulicity increases thyroid tumor risk, so the FDA issued a boxed warning for thyroid cancer risk with Trulicity. It should not be used with a family history of MTC. Tell your healthcare team right away if you notice a lump in your neck or symptoms that could suggest thyroid cancer, such as trouble swallowing, shortness of breath, or a hoarse voice that doesn’t go away.
You don’t need to completely avoid any specific foods while taking Trulicity. However, some foods and drinks may worsen side effects or affect blood sugar levels, including spicy foods, high-fat foods, processed meats, refined carbohydrates, sugary foods and drinks, and alcohol. Talk with your healthcare team if you’re unsure which foods are best for you.
Eli Lilly and Company. (2024). Trulicity (dulaglutide) injection, for subcutaneous use: Full prescribing information and boxed warning summary documentation. Indianapolis, IN: Eli Lilly and Company. https://www.trulicity.com/prescribing-information.pdf
U.S. Food and Drug Administration. (2020). FDA approves dulaglutide to minimize major adverse cardiovascular events in adults with type 2 diabetes. Silver Spring, MD: FDA. https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-trulicity-cardiovascular-risk-reduction
American Diabetes Association. (2024). Standards of care in diabetes—2024: Pharmacologic approaches to glycemic treatment and cardiovascular risk reduction profiles. Diabetes Care, 47(Suppl. 1), S158-S178. https://diabetesjournals.org/care/issue/47/Supplement_1
Get a 5% discount for the 1st order after registration
Create Account